KR20220155980A - 항-뮐러 호르몬 폴리펩티드 - Google Patents

항-뮐러 호르몬 폴리펩티드 Download PDF

Info

Publication number
KR20220155980A
KR20220155980A KR1020227018295A KR20227018295A KR20220155980A KR 20220155980 A KR20220155980 A KR 20220155980A KR 1020227018295 A KR1020227018295 A KR 1020227018295A KR 20227018295 A KR20227018295 A KR 20227018295A KR 20220155980 A KR20220155980 A KR 20220155980A
Authority
KR
South Korea
Prior art keywords
gly
ala
amh
leu
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227018295A
Other languages
English (en)
Korean (ko)
Inventor
크레이크 안토니 해리슨
켈리 루이즈 월튼
Original Assignee
모나쉬 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904097A external-priority patent/AU2019904097A0/en
Application filed by 모나쉬 유니버시티 filed Critical 모나쉬 유니버시티
Publication of KR20220155980A publication Critical patent/KR20220155980A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227018295A 2019-10-30 2020-10-30 항-뮐러 호르몬 폴리펩티드 Ceased KR20220155980A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904097 2019-10-30
AU2019904097A AU2019904097A0 (en) 2019-10-30 Anti-mullerian hormone polypeptides
PCT/AU2020/051187 WO2021081601A1 (en) 2019-10-30 2020-10-30 Anti-mullerian hormone polypeptides

Publications (1)

Publication Number Publication Date
KR20220155980A true KR20220155980A (ko) 2022-11-24

Family

ID=75714709

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018295A Ceased KR20220155980A (ko) 2019-10-30 2020-10-30 항-뮐러 호르몬 폴리펩티드

Country Status (8)

Country Link
US (1) US20220411477A1 (https=)
EP (1) EP4051699A4 (https=)
JP (1) JP2023501308A (https=)
KR (1) KR20220155980A (https=)
CN (1) CN114945588A (https=)
AU (1) AU2020373165A1 (https=)
CA (1) CA3156607A1 (https=)
WO (1) WO2021081601A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049960A1 (en) * 2023-08-30 2025-03-06 University Of Cincinnati Enhancing the production of anti-mullerian hormone through modification of its prodomain
WO2025085972A1 (en) * 2023-10-27 2025-05-01 Monash University Anti-mullerian hormone agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009012357A2 (en) * 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
WO2010017290A1 (en) * 2008-08-05 2010-02-11 The Trustees Of Columbia University In The City Of New York Müllerian inhibiting substance (mis) analogues
CA2837472A1 (en) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
AU2013342190B2 (en) * 2012-11-09 2018-11-08 Ansh Labs Llc Antibody compositions and immunoassay methods to detect isoforms of Anti-Mullerian Hormone
US11230583B2 (en) * 2015-11-26 2022-01-25 Hudson Institute of Medical Research Inhibin analogs
EP3257867A1 (fr) * 2016-06-17 2017-12-20 Biomérieux Procédé de préparation d'anticorps anti-amh et leurs utilisations
WO2018112168A1 (en) * 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
US11261225B2 (en) * 2017-02-10 2022-03-01 Institute For Cancer Research Chimera of bone morphogenic protein 2 and the Müllerian-inhibiting substance type II receptor binding region of Müllerian-inhibiting substance

Also Published As

Publication number Publication date
US20220411477A1 (en) 2022-12-29
CN114945588A (zh) 2022-08-26
JP2023501308A (ja) 2023-01-18
WO2021081601A1 (en) 2021-05-06
AU2020373165A1 (en) 2022-05-26
CA3156607A1 (en) 2021-05-06
EP4051699A1 (en) 2022-09-07
EP4051699A4 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
AU2022271391A1 (en) Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
US12544423B2 (en) C3b binding polypeptide
JPH10512440A (ja) サイトカイン”ｌｅｒｋ−７”
EP3738977B1 (en) Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same
KR20160048103A (ko) Vegf-c 및 ccbe1의 치료적 용도
US20120322984A1 (en) Methods of reducing trail-induced apoptosis by trail isoforms
KR20220155980A (ko) 항-뮐러 호르몬 폴리펩티드
JP4249927B2 (ja) コラーゲン様新規蛋白ｃｌａｃおよびその前駆体、ならびにそれらをコードする遺伝子
EP1410802A1 (en) Cell death inducers for mast cells
JP2024525221A (ja) アルツハイマー病を治療するためのｓｏｒｌａミニ受容体
EP4538370A1 (en) Fusion protein containing truncated iga protease and use thereof
WO2018154584A1 (en) Chimeras of soluble dr3 and pro-tace domain and use thereof
WO2025085972A1 (en) Anti-mullerian hormone agonists
EP2706113B1 (en) Synthetic peptide capable of inducing expression of type-2 tnf receptor and use thereof
JP2000125888A (ja) シアロアドヘシンファミリ―メンバ――３
US11136368B2 (en) Cancer treatment using CX26 blocking peptides
JP2005160473A (ja) 絨毛外栄養膜細胞特異的蛋白質
US20100168386A1 (en) Fusion protein carrying neurotrophin across the blood-brain barrier, encoding gene and uses thereof
JP2008161074A (ja) ｃａｖｅｏｌｉｎ−１−Ｆｃγ１融合タンパク質及びその使用
JPWO1997042319A1 (ja) 新規Ｆａｓ抗原誘導体
KR20140121088A (ko) 신규한 소포체 막투과성 단백질

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601